Allogene Therapeutics, Inc. financial data

Symbol
ALLO on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 882% % -25%
Debt-to-equity 34% % 30%
Return On Equity -58% % 0.48%
Return On Assets -43% % 6.3%
Operating Margin -1241814% % -260%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 224,730,144 shares 7.2%
Common Stock, Shares, Outstanding 223,163,672 shares 6.5%
Entity Public Float $354,000,000 USD -36%
Common Stock, Value, Issued $223,000 USD 6.2%
Weighted Average Number of Shares Outstanding, Basic 222,038,680 shares 6.1%
Weighted Average Number of Shares Outstanding, Diluted 222,038,680 shares 6.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD -100%
Research and Development Expense $166,492,000 USD -18%
General and Administrative Expense $58,527,000 USD -13%
Operating Income (Loss) $227,401,000 USD 24%
Nonoperating Income (Expense) $15,829,000 USD 10%
Net Income (Loss) Attributable to Parent $212,015,000 USD 25%
Earnings Per Share, Basic 0 USD/shares 37%
Earnings Per Share, Diluted 0 USD/shares 37%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $37,815,000 USD -26%
Cash, Cash Equivalents, and Short-term Investments $277,100,000 USD -31%
Assets, Current $260,719,000 USD -14%
Property, Plant and Equipment, Net $75,896,000 USD -15%
Operating Lease, Right-of-Use Asset $40,935,000 USD -12%
Other Assets, Noncurrent $3,513,000 USD -29%
Assets $439,771,000 USD -25%
Accounts Payable, Current $3,699,000 USD -33%
Employee-related Liabilities, Current $12,146,000 USD -4.1%
Contract with Customer, Liability, Current $86,000 USD 0%
Liabilities, Current $31,833,000 USD -2.3%
Operating Lease, Liability, Noncurrent $77,134,000 USD -9.4%
Other Liabilities, Noncurrent $15,475,000 USD 102%
Liabilities $124,442,000 USD -0.74%
Accumulated Other Comprehensive Income (Loss), Net of Tax $235,000 USD 50%
Retained Earnings (Accumulated Deficit) $1,971,899,000 USD -12%
Stockholders' Equity Attributable to Parent $315,329,000 USD -32%
Liabilities and Equity $439,771,000 USD -25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $52,929,000 USD 5.3%
Net Cash Provided by (Used in) Financing Activities $13,990,000 USD 748%
Net Cash Provided by (Used in) Investing Activities $6,176,000 USD -72%
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 223,163,672 shares 6.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $32,763,000 USD -2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $48,107,000 USD -22%
Deferred Tax Assets, Valuation Allowance $444,788,000 USD 11%
Deferred Tax Assets, Gross $455,824,000 USD 9.1%
Operating Lease, Liability $85,142,000 USD -8%
Depreciation $3,555,000 USD 1.4%
Payments to Acquire Property, Plant, and Equipment $99,000 USD 1138%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $211,937,000 USD 25%
Lessee, Operating Lease, Liability, to be Paid $109,453,000 USD -11%
Property, Plant and Equipment, Gross $145,410,000 USD -2.1%
Operating Lease, Liability, Current $8,008,000 USD 8.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two $13,613,000 USD 3.4%
Lessee, Operating Lease, Liability, to be Paid, Year One $13,164,000 USD 1.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $24,311,000 USD -18%
Lessee, Operating Lease, Liability, to be Paid, Year Three $14,078,000 USD 3.4%
Deferred Tax Assets, Operating Loss Carryforwards $243,798,000 USD 15%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $22,015,000 USD 17%
Lessee, Operating Lease, Liability, to be Paid, Year Four $15,480,000 USD 10%
Operating Lease, Payments $3,100,000 USD 3.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $3,099,000 USD -13%
Share-based Payment Arrangement, Expense $42,385,000 USD -22%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%